{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:03:17Z","timestamp":1771401797954,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Beta-thalassemia is typically inherited in an autosomal recessive manner and can result from a wide range of mutations affecting all stages of the gene expression pathway. Nonsense and frameshift mutations usually trigger nonsense-mediated mRNA decay (NMD). In rare cases, however, such mutations can lead to dominant \u03b2-thalassemia when NMD is bypassed, allowing the synthesis of truncated \u03b2-globin chains with dominant-negative effects. We describe a multigenerational family with a novel heterozygous two\u2013base pair insertion in the\n                    <jats:italic>HBB<\/jats:italic>\n                    gene (c.287_288insAC), resulting in a frameshift and a premature stop codon located downstream of the NMD threshold. This mutation causes dominantly inherited \u03b2-thalassemia with a broad clinical spectrum, ranging from mild anemia to transfusion dependency. The index patients\u2018 mother presented with anemia, splenomegaly, iron overload, and ultimately became transfusion-dependent. Her three children, all carriers of the same variant, exhibited variable degrees of anemia; two developed symptoms during adolescence that required pharmacological intervention. Luspatercept was effective in the affected mother and her daughter, improving hemoglobin levels, alleviating symptoms, and reducing transfusion requirements. Hydroxyurea was successfully used in the second daughter to stabilize hemoglobin levels. This case series expands the known spectrum of dominant \u03b2-thalassemia mutations and highlights the marked phenotypic variability even within a single family. Our findings support the use of Luspatercept and Hydroxyurea as therapeutic options. Long-term monitoring, including surveillance for complications related to iron overload, is essential for optimal clinical management.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06778-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:21:17Z","timestamp":1768969277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case series: a rare dominant form of \u03b2-thalassemia successfully treated by luspatercept"],"prefix":"10.1007","volume":"105","author":[{"given":"Pierre N.","family":"Allard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas E.","family":"Kulozik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim B.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"9","key":"6778_CR1","doi-asserted-by":"publisher","first-page":"a011692","DOI":"10.1101\/cshperspect.a011692","volume":"2","author":"TN Williams","year":"2012","unstructured":"Williams TN, Weatherall DJ (2012) World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med 2(9):a011692","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"6778_CR2","doi-asserted-by":"publisher","first-page":"a011700","DOI":"10.1101\/cshperspect.a011700","volume":"3","author":"SL Thein","year":"2013","unstructured":"Thein SL (2013) The molecular basis of \u03b2-thalassemia. Cold Spring Harb Perspect Med 3(5):a011700","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"6778_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5152\/eurasianjmed.2016.150013","volume":"48","author":"S Karakas","year":"2016","unstructured":"Karakas S, Tellioglu AM, Bilgin M, Omurlu IK, Caliskan S, Coskun S (2016) Craniofacial characteristics of thalassemia major patients. Eurasian J Med 48(3):204\u2013208","journal-title":"Eurasian J Med"},{"issue":"3","key":"6778_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1127\/anthranz\/65\/2007\/263","volume":"65","author":"T Redlefsen","year":"2007","unstructured":"Redlefsen T, Commentz J, Meigen C, Hermanussen M (2007) Reference values for height, weight and body mass index of German born Turkish children. Anthropol Anz 65(3):263\u2013274","journal-title":"Anthropol Anz"},{"issue":"10","key":"6778_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1515\/cclm-2018-1236","volume":"57","author":"J Zierk","year":"2019","unstructured":"Zierk J, Hirschmann J, Toddenroth D, Arzideh F, Haeckel R, Bertram A, Cario H, Fr\u00fchwald MC, Gro\u00df HJ, Groening A et al (2019) Next-generation reference intervals for pediatric hematology. Clin Chem Lab Med 57(10):1595\u20131607","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"6778_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12887-021-02756-3","volume":"21","author":"S Waelti","year":"2021","unstructured":"Waelti S, Fischer T, Wildermuth S, Leschka S, Dietrich T, Guesewell S, Mueller P, Ditchfield M, Markart S (2021) Normal sonographic liver and spleen dimensions in a central European pediatric population. BMC Pediatr 21(1):276","journal-title":"BMC Pediatr"},{"issue":"D1","key":"6778_CR7","doi-asserted-by":"publisher","first-page":"D1192","DOI":"10.1093\/nar\/gkaa959","volume":"49","author":"BM Giardine","year":"2021","unstructured":"Giardine BM, Joly P, Pissard S, Wajcman H, DH KC, Hardison RC, Patrinos GP (2021) Clinically relevant updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 49(D1):D1192\u2013d1196","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"6778_CR8","doi-asserted-by":"publisher","first-page":"e103020","DOI":"10.1371\/journal.pone.0103020","volume":"9","author":"P Kountouris","year":"2014","unstructured":"Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M (2014) IthaGenes: an interactive database for haemoglobin variations and epidemiology. PLoS ONE 9(7):e103020","journal-title":"PLoS ONE"},{"issue":"12","key":"6778_CR9","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1093\/emboj\/17.12.3484","volume":"17","author":"R Thermann","year":"1998","unstructured":"Thermann R, Neu-Yilik G, Deters A, Frede U, Wehr K, Hagemeier C, Hentze MW, Kulozik AE (1998) Binary specification of nonsense codons by splicing and cytoplasmic translation. Embo J 17(12):3484\u20133494","journal-title":"Embo J"},{"issue":"8","key":"6778_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/ng1403","volume":"36","author":"JA Holbrook","year":"2004","unstructured":"Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE (2004) Nonsense-mediated decay approaches the clinic. Nat Genet 36(8):801\u2013808","journal-title":"Nat Genet"},{"issue":"8","key":"6778_CR11","first-page":"522","volume":"23","author":"M Marsella","year":"2018","unstructured":"Marsella M, Ammirabile M, Di Matola T, Pepe A, Costantini S, Filosa A, Ricchi P (2018) Is there a difference in phenotype between males and females with non-transfusion-dependent thalassemia? A cross-sectional evaluation. Hematol (Amsterdam Netherlands) 23(8):522\u2013525","journal-title":"Hematol (Amsterdam Netherlands)"},{"issue":"2","key":"6778_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2141.1991.tb04548.x","volume":"79","author":"GW Hall","year":"1991","unstructured":"Hall GW, Franklin IM, Sura T, Thein SL (1991) A novel mutation (nonsense beta 127) in exon 3 of the beta globin gene produces a variable thalassaemic phenotype. Br J Haematol 79(2):342\u2013344","journal-title":"Br J Haematol"},{"issue":"6","key":"6778_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s002770050453","volume":"77","author":"PC Giordano","year":"1998","unstructured":"Giordano PC, Harteveld CL, Michiels JJ, Terpstra W, Schelfhout LJ, Appel IM, Batelaan D, van Delft P, Plug RJ, Bernini LF (1998) Phenotype variability of the dominant beta-thalassemia induced in four Dutch families by the rare cd121 (G\u2013>T) mutation. Ann Hematol 77(6):249\u2013255","journal-title":"Ann Hematol"},{"issue":"13","key":"6778_CR14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL et al (2020) A phase 3 trial of luspatercept in patients with Transfusion-Dependent \u03b2-Thalassemia. N Engl J Med 382(13):1219\u20131231","journal-title":"N Engl J Med"},{"issue":"11","key":"6778_CR15","first-page":"e31570","volume":"14","author":"IM Dighriri","year":"2022","unstructured":"Dighriri IM, Alrabghi KK, Sulaiman DM, Alruwaili AM, Alanazi NS, Al-Sadiq AA, Hadadi AM, Sahli BY, Qasem BA, Alotaibi MT et al (2022) Efficacy and safety of luspatercept in the treatment of \u03b2-Thalassemia: A systematic review. Cureus 14(11):e31570","journal-title":"Cureus"},{"issue":"8","key":"6778_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/08880018.2017.1354948","volume":"34","author":"AH Algiraigri","year":"2017","unstructured":"Algiraigri AH, Wright NAM, Paolucci EO, Kassam A (2017) Hydroxyurea for lifelong transfusion-dependent \u03b2-thalassemia: A meta-analysis. Pediatr Hematol Oncol 34(8):435\u2013448","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"6778_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.hemonc.2017.02.002","volume":"10","author":"AH Algiraigri","year":"2017","unstructured":"Algiraigri AH, Wright NAM, Paolucci EO, Kassam A (2017) Hydroxyurea for nontransfusion-dependent \u03b2-thalassemia: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 10(3):116\u2013125","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"Suppl 1","key":"6778_CR18","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.3109\/03630260903351809","volume":"33","author":"M Karimi","year":"2009","unstructured":"Karimi M (2009) Hydroxyurea in the management of thalassemia intermedia. Hemoglobin 33(Suppl 1):S177\u2013182","journal-title":"Hemoglobin"},{"issue":"7","key":"6778_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.23457","volume":"88","author":"VA Sheehan","year":"2013","unstructured":"Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE (2013) Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes. Am J Hematol 88(7):571\u2013576","journal-title":"Am J Hematol"},{"issue":"6","key":"6778_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ejh.12182","volume":"91","author":"MS Elalfy","year":"2013","unstructured":"Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR (2013) Therapeutic superiority and safety of combined hydroxyurea with Recombinant human erythropoietin over hydroxyurea in young \u03b2-thalassemia intermedia patients. Eur J Haematol 91(6):522\u2013533","journal-title":"Eur J Haematol"},{"issue":"16","key":"6778_CR21","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2021011045","volume":"139","author":"M Cazzola","year":"2022","unstructured":"Cazzola M (2022) Ineffective erythropoiesis and its treatment. Blood 139(16):2460\u20132470","journal-title":"Blood"},{"issue":"1","key":"6778_CR22","doi-asserted-by":"publisher","first-page":"e2024001","DOI":"10.4084\/MJHID.2024.001","volume":"16","author":"K Yang","year":"2024","unstructured":"Yang K, Liu X, Peng W, Hua F, Li L, Chen K, Zhang J, Luo S, Li W, Ding Y et al (2024) Effects of thalidomide on erythropoiesis and iron homeostasis in Transfusion-Dependent \u03b2-Thalassemia. Mediterranean J Hematol Infect Dis 16(1):e2024001","journal-title":"Mediterranean J Hematol Infect Dis"},{"issue":"17","key":"6778_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood.2019004719","volume":"136","author":"C Casu","year":"2020","unstructured":"Casu C, Pettinato M, Liu A, Aghajan M, Lo Presti V, Lidonnici MR, Munoz KA, O\u2019Hara E, Olivari V, Di Modica SM et al (2020) Correcting \u03b2-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood 136(17):1968\u20131979","journal-title":"Blood"},{"key":"6778_CR24","doi-asserted-by":"crossref","unstructured":"Matte A, Federti E, Kung C, Kosinski PA, Narayanaswamy R, Russo R, Federico G, Carlomagno F, Desbats MA, Salviati L et al (2021) The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a \u03b2-thalassemia mouse model. J Clin Invest 131(10):e144206.","DOI":"10.1172\/JCI144206"},{"issue":"6","key":"6778_CR25","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/bjh.20058","volume":"206","author":"KHM Kuo","year":"2025","unstructured":"Kuo KHM, Layton DM, Lal A, Vichinsky EP, Dahlin JL, Shen S, Price GM, Gilroy KS, Estepp JH, Al-Samkari H (2025) Long-term efficacy and safety of mitapivat in non-transfusion-dependent \u03b1- or \u03b2-thalassaemia: an open-label phase 2 study. Br J Haematol 206(6):1764\u20131773","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06778-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:48Z","timestamp":1771398228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06778-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6778"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06778-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}